Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
NVO vs STLN — Stock Comparison
Compare NVO and STLN side-by-side on StoQuant: NVO Q-Score 58 vs STLN 50; analyst signal 61 vs —. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- NVO — Novo Nordisk A/S · Health Care · market cap $169.01B · Q-Score verdict Buy (58.0, grade B) · analyst signal 61/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 87/100, valuation 78/100 · weakest signals: analyst consensus 33/100, social sentiment 18/100. Full NVO research.
- STLN — Starling Oncology Inc. Common Stock · Health Care · Q-Score verdict Unrated (50.0) · strongest signals: competitive moat 100/100. Full STLN research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: NVO research · STLN research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.